Punctate Inner Choroidopathy (PIC)

Punctate inner choroidopathy, often shortened to PIC, is an eye condition that affects the choroid and the outer layers of the retina. The choroid is the thin layer of blood vessels that sits under the retina and provides oxygen and nutrients to keep the retina healthy. In PIC, tiny spots of inflammation form in this inner choroid and outer retina. Doctors see these spots as small, yellow-white dots when they look at the back of the eye after dilating the pupils. These dots are “punctate,” which means they are small and point-like. They tend to be clustered around the center of vision called the macula, but they can also appear in other areas of the posterior pole of the eye.

Punctate Inner Choroidopathy—often shortened to PIC—is a rare eye condition caused by inflammation at the back layer of the eye where the retina and its blood-rich support tissue (the choroid) meet. In PIC, tiny, round, yellow-white spots appear in the central retina. These spots are small scars within the inner choroid and the retinal pigment epithelium (RPE). The condition most often affects people who are short-sighted (myopic) and is more common in young adult women. Vision can blur, a dark patch can appear in the center, and straight lines may look bent. The main long-term risk is the growth of abnormal new blood vessels under the retina, called choroidal neovascularization (CNV), which can leak and scar, leading to permanent central vision loss if not treated quickly. EyeWikiPMC

PIC is considered one of the “white dot syndromes,” which is a group of conditions where small inflammatory spots appear in the choroid and retina. PIC often occurs in young to middle-aged adults, and it is more common in people who are near-sighted (myopic). Many people with PIC are otherwise healthy. The exact cause is not fully known, so the condition is called idiopathic, which means “arising from an unknown cause.” Even though the cause is not fully known, PIC follows a pattern that eye doctors can recognize, diagnose, and monitor carefully.

One important point about PIC is the risk of choroidal neovascularization (CNV), which means fragile new blood vessels can grow in the wrong place under or within the retina. These abnormal vessels can leak or bleed and threaten central vision. Not everyone with PIC gets CNV, but it is a key reason why regular follow-up and timely imaging tests are so important. Many people with PIC have little to no inflammation in the vitreous gel of the eye, so doctors often describe PIC as “no-vitritis” or “quiet vitreous” compared with some other inflammatory eye diseases.

PIC matters because it affects the layer of the eye that is critical for sharp central vision. The small inflammatory spots can heal with scars that may subtly change vision or leave small blind spots. If CNV develops, vision can become distorted or blurred, and treatment may be needed to prevent permanent damage. Early recognition, simple home monitoring, and modern imaging can help find changes early, which often improves outcomes.

PIC can occur in both women and men, but it is often reported in young women with moderate to high myopia. Many patients are otherwise healthy. Episodes can come and go, and some people have long periods without new spots. Pregnancy, hormonal shifts, and stress have been reported around the time PIC shows up or becomes active, but these are associations and not proven direct causes. Because PIC shares features with other “white dot” conditions, a careful exam and testing plan helps make sure the diagnosis is precise.

---

Types

Doctors do not have one strict “types list” for PIC like some other diseases, but they often use practical groupings that describe what they see and how the disease behaves. These labels help guide monitoring and treatment decisions.

1. Classic PIC without CNV
   This description means there are typical small inner choroidal spots and scars, with no sign of abnormal new vessels. Vision may be near normal or only mildly affected, and the key goal is watchful follow-up.

2. PIC with active CNV
   This describes PIC where abnormal new vessels are present and are leaking or causing swelling or bleeding. This type often needs prompt treatment and close imaging follow-up.

3. Recurrent PIC
   This describes cases where new spots appear in bursts over time. Patients may have quiet periods followed by new activity. The pattern helps doctors adjust the monitoring plan.

4. Unilateral PIC
   This label means only one eye shows PIC changes. The other eye still needs monitoring because changes can appear later.

5. Bilateral PIC
   This label means both eyes are affected. Sometimes one eye is active while the other is quiet. The overall risk of visual change may be higher if both eyes are involved.

6. Macula-dominant PIC
   In this description, most spots and scars cluster near the central retina. Symptoms may be more noticeable because the macula handles sharp, detailed vision.

7. Peripheral-involving PIC
   In some people, spots can extend away from the center. Central vision may be less affected at first, so careful imaging is needed to map all areas involved.

8. PIC with subretinal fibrosis
   Some healed areas develop small patches of scar tissue under the retina. These scars can be stable, but their location and size influence vision.

9. Pregnancy-associated PIC activity
   Some patients report activity around pregnancy. The relationship is not fully understood, so this is a descriptive label that reminds the care team to watch more closely during this time.

10. PIC with coexisting autoimmune features
    A small group of patients has personal or family histories that suggest autoimmune tendencies. This label does not prove a cause, but it shapes the work-up and follow-up plan.

---

Causes

PIC is idiopathic, which means no single proven cause is known. Instead of one cause, most experts think several risk factors and triggers may work together in a person who is already susceptible. The list below groups common ideas doctors consider. Each item is written as a possibility or association, not as a guaranteed cause.

1. Underlying immune sensitivity
   Many white dot diseases behave like the immune system is reacting in a focused way in the eye. In PIC, the immune system may target parts of the outer retina or choroid, leading to small spots of inflammation.

2. Genetic susceptibility
   Some people may inherit immune system patterns that respond differently to triggers. A genetic tendency does not mean the disease will occur, but it may raise the baseline risk.

3. Female sex and hormonal context
   PIC is often reported in women of child-bearing age. Hormonal changes can influence the immune system, and timing around life events may play a role for some patients.

4. Myopia (near-sightedness)
   Many patients with PIC are near-sighted. A longer eye shape and subtle structural differences in the choroid and retina may change how these tissues react to inflammation.

5. Micro-injury or stress in the outer retina
   Everyday visual stress or minor metabolic strain in the photoreceptor layer might make the tissue more vulnerable to small inflammatory events.

6. Viral illness as a nonspecific trigger
   A cold or flu-like illness can briefly activate the immune system. In a susceptible person, this burst of immune activity might trigger focal eye inflammation.

7. Post-infectious immune modulation
   After an infection, the immune system can “reset” in different ways. Rarely, that reset might include misdirected reactions in the eye.

8. Environmental stressors
   Poor sleep, extreme work hours, or emotional stress do not cause PIC directly, but they may nudge immune balance in a way that allows a flare in someone predisposed.

9. Smoking or smoke exposure
   Smoke can alter blood vessels and immune behavior. While not a proven cause, avoiding smoke is considered helpful for general eye health and may reduce risk in inflammatory eye disease.

10. Systemic low-grade inflammation
    Some people live with mild, fluctuating body-wide inflammation from diet, weight, or other factors. This can “prime” the immune system and influence eye responses.

11. Autoimmune background in the family
    Families with autoimmune diseases like thyroid disease, vitiligo, or rheumatoid arthritis may point to a general immune tendency. This is a clue, not a cause.

12. Local choroidal circulation variation
    Subtle changes in blood flow under the retina might contribute to tissue stress. When tissue is stressed, small inflammatory spots may appear.

13. Vitamin D insufficiency
    Vitamin D influences immune balance. Low levels are common in the general population and may modulate immune activity, although this is an association rather than a proven driver.

14. Pregnancy-related immune shifts
    The immune system changes during pregnancy. Some inflammatory eye conditions quiet down, and others fluctuate. In some patients, PIC activity can appear around this time.

15. Recent major life change
    A relocation, new job, or serious illness can raise stress and alter routines. Immune balance can shift during these periods and might allow an episode in a susceptible eye.

16. Gut microbiome imbalance
    The gut community of bacteria interacts with the immune system. Changes here may alter overall immune tone, with uncertain but plausible effects on eye inflammation.

17. Sunlight and light exposure patterns
    Strong light can stress photoreceptors if unprotected. This is not a direct cause, but safe light habits and UV protection are healthy for eyes in general.

18. Coexisting subtle autoimmune disease
    Some people later discover mild autoimmune conditions. These conditions may share immune pathways with PIC and could help explain the eye pattern.

19. Vaccination or immune-stimulating events
    Very rarely, immune stimulation of any kind has been temporally linked to inflammatory eye activity. Temporal links do not prove causation, and vaccination remains important for overall health; this is mentioned only as a general immune-system consideration.

20. Truly idiopathic onset with no clear trigger
    Many patients have PIC without any obvious risk factor or trigger. This reminds us that our knowledge is still growing and that careful follow-up is key even when no cause is found.

---

Symptoms

Symptoms of PIC depend on where the spots form, how active the inflammation is, and whether CNV has developed. Some people have mild symptoms, and others notice changes that affect reading and detailed tasks. Each symptom below is explained in simple terms.

1. Blurry central vision
   Words on a page or faces at a normal distance can look slightly fuzzy or smeared.

2. Distorted vision (metamorphopsia)
   Straight lines can look bent or wavy, and squares can look uneven. This is often noticed on an Amsler grid or while reading.

3. Small dark or gray spot in the center or near the center (paracentral scotoma)
   A tiny area can look dim, blank, or gray, which becomes more obvious during reading or when looking at a plain background.

4. Flashes or sparkles of light (photopsias)
   Brief, flickering lights can appear in the area where the spots are active, especially in dim light.

5. Reduced contrast
   Black-on-white text does not “pop” as much, and scenes can look flat or washed out.

6. Color vision changes
   Colors may seem less vivid or subtly different, especially reds and greens.

7. Sensitivity to bright light (photophobia)
   Sunlight or screens can feel harsh, and the eyes may prefer dimmer environments.

8. Difficulty reading small print
   Letters can fade, jump, or break, even with glasses or contact lenses.

9. Trouble recognizing faces at a glance
   Facial features may look soft or slightly distorted, especially in low light or at a distance.

10. Poorer night vision
    Dim settings feel more challenging, and moving from bright to dark areas takes longer to adjust.

11. Headache or eye strain after near work
    Extra effort to keep letters clear can cause aching or pressure around the eyes.

12. Increased need for brighter light to read
    People may prefer stronger task lighting to make print more comfortable.

13. Intermittent “shadow” in the central area
    A faint, moving shadow can appear in the same place when looking around.

14. Sudden worsening with new bleeding or leakage (if CNV forms)
    Vision can drop quickly and become more distorted if new vessels leak. This is a warning sign that needs prompt care.

15. Feeling that one eye is “not pulling its weight”
    When using both eyes, the weaker eye contributes a blur or a distortion that becomes more obvious if the other eye is covered.

---

Diagnostic approach and key tests

Doctors diagnose PIC by combining history, careful eye examination, and targeted tests. The goal is to confirm the pattern of PIC, look for CNV, and rule out mimicking diseases like ocular histoplasmosis, multifocal choroiditis, serpiginous choroiditis, uveitis of other causes, and infections like syphilis or tuberculosis. Below are 20 useful tests grouped into Physical Exam, Manual Tests, Lab and Pathological Tests, Electrodiagnostic Tests, and Imaging Tests. Each test explains what it is and why it helps.

A) Physical Exam

1. Best-corrected visual acuity
   This is the standard eye chart test with the best glasses correction. It measures how clearly each eye sees and helps track changes over time. A drop in acuity can signal active spots, swelling, or CNV.

2. Pupil exam for relative afferent pupillary defect (RAPD)
   The doctor shines a light to see how each pupil reacts. In most PIC cases, there is no RAPD because disease is often focal and not optic-nerve based, but the test helps rule out other problems.

3. Color vision testing (e.g., Ishihara plates)
   Simple color dot tests can show subtle color weakness. Changes can reflect outer retinal stress near the macula.

4. Contrast sensitivity testing
   Special charts with faint gray letters measure how well the eye detects low-contrast details. Reduced contrast often matches patient complaints even when standard acuity looks reasonable.

5. Slit-lamp and dilated fundus examination
   After dilating the pupils, the doctor inspects the vitreous, retina, and choroid. In PIC, small yellow-white spots and subtle scars are seen, usually without much vitreous haze. Any signs of bleeding or fluid raise concern for CNV.

B) Manual Tests

6. Amsler grid at home and in clinic
   This is a simple square grid of lines the patient views at reading distance. Wavy lines, missing boxes, or dark patches suggest macular disturbance. People with PIC can use this grid at home to notice early changes and call promptly.

7. Confrontation visual fields
   The doctor checks side-by-side fields by asking the patient to count fingers or see small targets. While not as precise as machine-based fields, it can show larger defects or confirm central/paracentral spots.

8. Pinhole and quick refraction check
   Looking through a pinhole or testing a quick prescription helps separate blur from refractive error versus blur from retinal changes. If the pinhole does not improve clarity, the retina is the likely source.

C) Lab and Pathological Tests

9. Inflammation markers (ESR, CRP)
   These blood tests look for general body inflammation. They are often normal in PIC but can guide the broader search for other conditions if the pattern is unclear.

10. Syphilis serology (e.g., treponemal and non-treponemal tests)
    Syphilis can mimic many eye diseases. A simple blood test helps rule it out because the treatment is completely different.

11. Tuberculosis screening (e.g., IGRA blood test or tuberculin skin test)
    TB can affect the choroid and look like inflammatory spots. Screening is useful in endemic areas or if imaging suggests a TB pattern.

12. Autoimmune and granulomatous disease screening (e.g., ANA, serum ACE when sarcoidosis is suspected)
    These tests are not specific for PIC but help rule in or out other inflammatory causes that can mimic PIC in appearance.

D) Electrodiagnostic Tests

13. Full-field electroretinogram (ERG)
    This test measures the electrical responses of the entire retina to flashes of light. In PIC, full-field ERG is often normal because the disease is focal, but it helps exclude widespread retinal diseases.

14. Multifocal ERG (mfERG)
    This test maps function in many small regions of the macula. It can show localized depression of function that matches the location of PIC spots and scars.

15. Visual evoked potentials (VEP)
    VEP measures electrical signals from the visual cortex after a visual pattern is shown. It helps rule out optic-nerve pathway problems if the clinical picture is mixed.

E) Imaging Tests

16. Optical coherence tomography (OCT)
    OCT is a non-contact scan that creates cross-section images of the retina. In PIC, OCT can show tiny disruptions in the outer retina, subtle swelling, or signs of CNV like fluid pockets under or within the retina. OCT is essential for baseline and follow-up.

17. OCT angiography (OCT-A)
    OCT-A maps blood flow in the retina and choroid without dye. In PIC it can reveal small abnormal networks of vessels that suggest early CNV, even before leakage is obvious on other tests.

18. Fluorescein angiography (FA)
    FA uses a dye injected into a vein with rapid photos of the retina. It shows leakage from abnormal vessels and highlights areas where the retinal pigment epithelium is disturbed. It is a classic tool to confirm CNV activity and guide treatment decisions.

19. Indocyanine green angiography (ICGA)
    ICGA uses a dye that visualizes deeper choroidal vessels. It can outline choroidal changes more clearly than FA in some cases and helps confirm the white-dot pattern typical of PIC.

20. Fundus autofluorescence (FAF)
    FAF uses natural signals from retinal pigment cells to map stress and damage. In PIC, active or healing spots can show characteristic bright or dark signals that help track the life cycle of each lesion.

Non-pharmacological treatments (therapies and others)

These are supportive strategies you can use alongside medical care. They do not replace doctor-prescribed treatment, especially if CNV develops.

1. Education and early-warning self-monitoring
   Purpose: Catch new symptoms fast.
   Mechanism: Knowing what new floaters, flashing lights, bent lines (metamorphopsia), or a gray spot mean helps you seek timely care. Use an Amsler grid daily; report changes immediately.

2. Regular specialist follow-up
   Purpose: Detect silent activity before vision drops.
   Mechanism: Optical coherence tomography (OCT), fundus autofluorescence, and angiography show subtle swelling or CNV early.

3. Light and glare management
   Purpose: Reduce discomfort from inflammation-related light sensitivity.
   Mechanism: Broad-brim hats and quality sunglasses (UV-blocking) lower retinal light stress and glare.

4. Smoking cessation
   Purpose: Lower risk of CNV and poor healing.
   Mechanism: Smoking increases oxidative stress and impairs choroidal blood flow; quitting reduces these stresses.

5. Cardio-metabolic health (blood pressure, lipids, glucose)
   Purpose: Protect the tiny blood vessels under the retina.
   Mechanism: Healthy vessels mean less ischemic drive for abnormal vessel growth.

6. Anti-inflammatory dietary pattern
   Purpose: Support retinal health naturally.
   Mechanism: A diet rich in leafy greens, colorful vegetables, legumes, nuts, whole grains, and fish provides lutein, zeaxanthin, omega-3s, and antioxidants that reduce oxidative stress in photoreceptors and RPE.

7. Adequate hydration
   Purpose: Support overall ocular perfusion.
   Mechanism: Proper hydration maintains plasma volume and microvascular flow.

8. Consistent, moderate exercise
   Purpose: Improve vascular health and reduce systemic inflammation.
   Mechanism: Exercise lowers inflammatory cytokines and improves endothelial function.

9. Sleep hygiene
   Purpose: Stabilize immune balance.
   Mechanism: Regular sleep reduces cortisol swings that can worsen inflammation.

10. Stress-reduction training
    Purpose: Limit flares potentially linked to immune activation.
    Mechanism: Mindfulness, breathing drills, or CBT lower sympathetic tone and systemic inflammatory signals.

11. Digital eye-strain rules
    Purpose: Reduce near-work discomfort in myopes commonly affected by PIC.
    Mechanism: The “20-20-20 rule” (every 20 minutes, look 20 feet away for 20 seconds) relaxes accommodative stress and improves blink rate.

12. Protective eyewear for sports/DIY
    Purpose: Prevent trauma-related complications in an already vulnerable macula.
    Mechanism: Safety lenses stop impact or foreign bodies.

13. Contact lens hygiene (if used)
    Purpose: Avoid superimposed infections that can confuse the picture.
    Mechanism: Proper cleaning and replacement schedules reduce microbial risk.

14. Limit excessive alcohol
    Purpose: Reduce oxidative stress and maintain good sleep.
    Mechanism: Alcohol can disturb sleep architecture and increase systemic inflammation.

15. Blue-light and contrast settings optimization
    Purpose: Increase comfort with screens.
    Mechanism: Adjusting brightness/contrast and using dark mode where helpful eases photophobia.

16. Low-vision aids when needed
    Purpose: Maximize functional vision if central scotoma develops.
    Mechanism: High-contrast lighting, magnifiers, and electronic zoom tools enlarge text and enhance contrast.

17. Vaccination up to date (general health)
    Purpose: Reduce risk of severe infections that could complicate care.
    Mechanism: Preventing systemic infections avoids immune surges and interruptions in therapy.

18. Medication list review
    Purpose: Avoid drug interactions that elevate inflammation or thin blood if procedures are needed.
    Mechanism: Your clinician checks for agents that raise bleeding risk or interact with immunosuppressants.

19. Pregnancy and family-planning counseling
    Purpose: Safely navigate therapy choices.
    Mechanism: Many PIC drugs are not pregnancy-safe; planning prevents exposure.

20. Prompt care for any new central distortion
    Purpose: Protect the macula from scarring.
    Mechanism: Early treatment of CNV with anti-VEGF can preserve vision.

---

Drug treatments

Important: Doses below are typical ranges for adults and are individualized. Decisions depend on disease activity, scan findings, side-effect risks, pregnancy status, and other medical history.

1. Prednisone (systemic corticosteroid)
   Class: Corticosteroid.
   Typical dose/time: ~0.5–1 mg/kg/day orally for active inflammation; taper over weeks.
   Purpose: Calm acute inflammation and settle active lesions.
   Mechanism: Broad suppression of cytokines and immune cell activity.
   Common side effects: Elevated blood sugar, mood changes, insomnia, blood pressure rise, weight gain, infection risk, cataract and glaucoma with prolonged use.

2. Methylprednisolone IV “pulse”
   Class: Intravenous corticosteroid for severe/vision-threatening activity.
   Typical dose/time: 500–1,000 mg IV daily for 3 days, then oral taper.
   Purpose: Rapid control when the macula is threatened.
   Mechanism/SEs: As above; IV adds transient flushing and blood-pressure spikes.

3. Mycophenolate mofetil (MMF)
   Class: Antimetabolite immunomodulator.
   Typical dose/time: 1,000–1,500 mg twice daily.
   Purpose: Steroid-sparing long-term control to prevent relapses.
   Mechanism: Blocks lymphocyte purine synthesis, reducing auto-reactive activity.
   Common side effects: GI upset, low white counts, infection risk; avoid in pregnancy.

4. Azathioprine
   Class: Antimetabolite.
   Typical dose/time: ~1–2.5 mg/kg/day.
   Purpose: Long-term steroid-sparing control.
   Mechanism: Inhibits DNA synthesis in rapidly dividing immune cells.
   Side effects: Cytopenias, liver enzyme rise; TPMT testing helps dosing safety.

5. Methotrexate
   Class: Antimetabolite (weekly).
   Typical dose/time: 15–25 mg once weekly orally or subcutaneously, plus folic acid.
   Purpose: Chronic control when MMF/azathioprine are unsuitable.
   Mechanism: Folate pathway inhibition dampens lymphocyte proliferation.
   Side effects: Liver toxicity, mouth sores, cytopenias; avoid in pregnancy.

6. Cyclosporine
   Class: Calcineurin inhibitor.
   Typical dose/time: ~2–5 mg/kg/day in divided doses.
   Purpose: Steroid-sparing agent for recurrent inflammation.
   Mechanism: Blocks T-cell activation via calcineurin.
   Side effects: Kidney dysfunction, hypertension, gum changes.

7. Adalimumab
   Class: Anti-TNF-α monoclonal antibody (biologic).
   Typical dose/time: 80 mg day 0, then 40 mg every 2 weeks (uveitis schedule).
   Purpose: Steroid-sparing control of noninfectious posterior uveitis patterns; sometimes used for PIC with recurrent activity.
   Mechanism: Neutralizes TNF-α, a key inflammatory signal.
   Side effects: Injection reactions, infection risk (TB screening needed). Evidence from VISUAL trials supports efficacy in noninfectious uveitis. New England Journal of MedicineScienceDirect

8. Infliximab
   Class: IV anti-TNF-α monoclonal antibody.
   Typical dose/time: ~5 mg/kg IV at weeks 0, 2, 6, then every 4–8 weeks.
   Purpose: Option for refractory inflammation when other agents fail.
   Mechanism/SEs: TNF-α blockade; infusion reactions, infections.

9. Anti-VEGF injections (Ranibizumab or Aflibercept)
   Class: Vascular endothelial growth factor (VEGF) inhibitors.
   Typical dose/time: Ranibizumab 0.5 mg; Aflibercept 2 mg; given into the eye at intervals then “treat-and-extend.”
   Purpose: First-line for CNV due to PIC to stop leakage and preserve central vision.
   Mechanism: Blocks VEGF-driven abnormal vessel growth and leakage.
   Side effects: Rare infection (endoophthalmitis), transient eye pressure rise. Strong clinical experience and studies show anti-VEGF is effective in inflammatory CNV, including PIC. AAOKarger

10. Intravitreal corticosteroids (Triamcinolone, Dexamethasone implant; Fluocinolone implant)
    Class: Local ocular steroids.
    Typical dose/time: Triamcinolone ~4 mg PRN; Dexamethasone implant 0.7 mg every 3–6 months; Fluocinolone 0.19 mg implant releases drug for up to 36 months.
    Purpose: Reduce macular inflammation and edema when systemic therapy is unsuitable.
    Mechanism: Potent local anti-inflammatory effect.
    Side effects: Cataract, eye-pressure rise requiring drops or surgery.

---

Dietary molecular supplements

Evidence in PIC is limited; these are supportive for general retinal health. Discuss with your clinician, especially if you take blood thinners, are pregnant, or have other conditions.

1. Lutein (10 mg/day)
   Supports macular pigment; filters blue light; antioxidant action in photoreceptors and RPE.

2. Zeaxanthin (2 mg/day)
   Works with lutein to stabilize macular pigment and reduce oxidative stress.

3. Omega-3 (DHA/EPA ~1,000 mg/day combined)
   Anti-inflammatory lipid mediators (resolvins/protectins) may support retinal cell membranes.

4. Vitamin D (1,000–2,000 IU/day if deficient)
   Immune-modulating effects; deficiency is common and correctable.

5. Vitamin C (500–1,000 mg/day)
   A water-soluble antioxidant supporting collagen and capillary health.

6. Vitamin E (up to 200 IU/day unless contraindicated)
   Fat-soluble antioxidant protecting photoreceptor membranes.

7. Zinc (10–25 mg/day)
   Cofactor in retinal enzymes; excessive dosing can cause copper deficiency—balance matters.

8. Copper (1–2 mg/day when on zinc)
   Prevents copper deficiency anemia from long-term zinc use.

9. N-acetylcysteine (600–1,200 mg/day)
   Boosts glutathione, an intracellular antioxidant; may help oxidative redox balance.

10. Curcumin (up to 500–1,000 mg/day with piperine for absorption)
    Plant-derived anti-inflammatory that can dampen NF-κB signaling; check for gallbladder or anticoagulant interactions.

---

Regenerative / stem-cell-related options

Plain truth: there are no approved stem-cell cures for PIC today. Some regenerative strategies are experimental and should be limited to registered clinical trials. Below are therapies often considered when PIC behaves like stubborn noninfectious posterior uveitis (immune-modulating), plus a realistic note on regenerative ideas.

1. Adalimumab (anti-TNF-α)
   Dose: 80 mg then 40 mg every 2 weeks.
   Function/Mechanism: Dampens TNF-α–driven inflammation; steroid-sparing; supported in noninfectious uveitis. New England Journal of Medicine

2. Infliximab (anti-TNF-α, IV)
   Dose: 5 mg/kg at 0, 2, 6 weeks, then every 4–8 weeks.
   Function/Mechanism: Systemic TNF-α blockade for refractory cases.

3. Tocilizumab (anti-IL-6 receptor)
   Dose: Common uveitis regimens include 162 mg subcutaneously every 1–2 weeks or IV per protocol.
   Function/Mechanism: Reduces IL-6–mediated inflammation; sometimes used for uveitic macular edema when other agents fail.

4. Rituximab (anti-CD20 B-cell therapy)
   Dose: IV infusions per rheumatology/uveitis protocols.
   Function/Mechanism: Depletes B cells that present antigen and produce inflammatory mediators in select refractory uveitis phenotypes.

5. Interferon-α2a
   Dose: Titrated subcutaneously under specialist care.
   Function/Mechanism: Immunomodulator used off-label in difficult inflammatory chorioretinopathies.

6. RPE/retinal stem-cell–based therapies (investigational)
   Dose: Trial-specific.
   Function/Mechanism: Aim to replace or support damaged RPE/photoreceptors. Not standard of care for PIC; discuss only within monitored clinical trials.

---

Procedures/surgeries

1. Intravitreal anti-VEGF injections
   Procedure: A tiny injection in the white of the eye delivers VEGF blocker into the vitreous.
   Why: This is the front-line treatment for CNV due to PIC and can rapidly improve or stabilize central vision by stopping leakage. AAO

2. Photodynamic therapy (PDT)
   Procedure: A light-activated drug (verteporfin) is given by IV, then a cool laser targets the CNV to close it.
   Why: Considered when anti-VEGF is not available, not tolerated, or lesions are suitable; historically used and still an option in selected inflammatory CNV. PMCNature

3. Pars plana vitrectomy for non-clearing hemorrhage
   Procedure: Microsurgery removes vitreous blood and may allow submacular blood displacement with tissue plasminogen activator (tPA) and gas.
   Why: To clear vision and reduce toxic effects of trapped blood if a large bleed occurs from CNV.

4. Cataract surgery (phacoemulsification with IOL)
   Procedure: Clouded lens removal with lens implant.
   Why: Long-term steroids can accelerate cataract; surgery restores clarity once inflammation is controlled.

5. Glaucoma surgery (e.g., trabeculectomy or MIGS)
   Procedure: Creates a new outflow for eye fluid to lower pressure.
   Why: Some patients develop steroid-induced ocular hypertension or glaucoma; surgery is a backup if drops and steroid tapering are insufficient.

---

Prevention tips

1. Do not skip retina checks—regular OCT can catch trouble early.

2. Use an Amsler grid each day; call promptly if lines bend or a gray spot appears.

3. Quit smoking; it harms retinal blood flow.

4. Control blood pressure, cholesterol, and glucose with your primary-care team.

5. Wear UV-blocking sunglasses outdoors.

6. Maintain an anti-inflammatory diet and healthy weight.

7. Keep vaccinations up to date to avoid severe infections during immunosuppression.

8. Plan pregnancy in advance; many PIC medicines are not pregnancy-safe.

9. Practice careful contact-lens hygiene, or use glasses if hygiene is difficult.

10. Avoid missed doses of prescribed therapy; communicate side effects early to adjust safely.

---

When to see a doctor urgently

• Sudden central blur, a dark or gray spot, or new distortion of straight lines.

• New flashes or a shower of floaters.

• Any drop in vision after you felt stable.

• Eye pain, severe redness, or sensitivity to light, especially if you are on injections or immunosuppression.

• Persistent headache with vision changes.

• Fever, cough, or other infection symptoms if you are on steroids or immunomodulators.

---

What to eat and what to avoid

Eat more of:

1. Leafy greens (spinach, kale) for lutein/zeaxanthin.

2. Colorful vegetables and berries for antioxidants.

3. Fatty fish (2–3 times/week) for omega-3s.

4. Nuts and seeds (small handful daily) for healthy fats.

5. Whole grains and legumes for fiber and steady blood sugar.

Limit or avoid:

1. Tobacco in any form.
2. Highly processed snacks rich in trans fats.
3. Sugary drinks and refined sweets that spike glucose.
4. Excess alcohol that disrupts sleep and raises inflammation.
5. Mega-dosing of supplements without clinician guidance (especially vitamin A, vitamin E, zinc).

---

Frequently asked questions

1. Is PIC the same as uveitis?
   PIC sits in the family of inflammatory “white dot” diseases. Many doctors manage it like noninfectious posterior uveitis because inflammation is in the back of the eye.

2. Why did I get PIC?
   The exact cause is unknown. Genetics, myopia, and immune factors likely interact. In most people there is no single trigger identified. PMC

3. Will I go blind?
   Most people do not go blind. The main risk is central vision loss from CNV. Rapid treatment, especially with anti-VEGF injections, often preserves good vision. AAO

4. How do doctors confirm PIC?
   By eye exam and imaging—especially OCT, fluorescein angiography, indocyanine green angiography, and fundus autofluorescence—that show typical lesions and any CNV.

5. Is there a cure?
   There is no permanent cure, but inflammation and CNV can be controlled. Many patients cycle through quiet periods and occasional flares.

6. Do the white spots go away?
   Active spots fade into small atrophic scars. Doctors track them with photos and autofluorescence imaging.

7. Why are anti-VEGF injections so important?
   Because they directly shut down the abnormal vessels that threaten the macula and central vision in PIC-related CNV. AAO

8. Are steroids safe?
   They work well short-term but can cause cataracts, glaucoma, infection risk, mood changes, and bone thinning if used long-term. That’s why steroid-sparing drugs are common.

9. What are “steroid-sparing” drugs?
   Medicines like mycophenolate, methotrexate, azathioprine, cyclosporine, and biologics (e.g., adalimumab) help keep inflammation controlled with less steroid exposure. New England Journal of Medicine

10. Is PDT still used?
    Less often now, but it can help selected inflammatory CNV when anti-VEGF is not suitable or as an adjunct. PMC

11. Can PIC affect both eyes?
    Yes; many patients have both eyes involved, though one eye can be worse. EyeWiki

12. Will glasses or contact lenses fix this?
    They correct refractive error but do not treat PIC itself. Medical treatment targets inflammation or CNV.

13. Can I prevent flares with diet alone?
    Diet supports eye health but does not replace medical therapy. Use diet as an add-on, not a substitute.

14. What about pregnancy?
    Several PIC medicines are unsafe in pregnancy. If pregnancy is possible, plan ahead with your ophthalmologist and obstetrician.

15. What is my long-term outlook?
    With regular monitoring and modern treatment—especially prompt anti-VEGF for CNV—many patients keep useful central vision for the long term. AAO

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 23, 2025.

PDF Document For This Disease Conditions References